Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
A randomized, double blind, study of dronabinol as a palliative agent in the treatment of
pain, inflammation, and other complications of sickle cell disease (SCD).